Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention

Trends in Molecular Medicine

Volumn 8, Issue 4 SUPPL., 2002, Pages

  Herrera, Roman ^a   Sebolt Leopold, Judith S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

ANGIOGENESIS; CANCER GROWTH; CANCER RESEARCH; CELL DIFFERENTIATION; CELL SURVIVAL; GROWTH REGULATION; HUMAN; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION;

ARENA;

EID: 0036216651     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02307-9     Document Type: Review

References (30)

1. The hallmarks of cancer
2. Growth factor signaling in cell survival: Implications for cancer treatment
3. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors
4. Signaling from Ras to Rac and beyond: Not just a matter of GEFs
5. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models
7. Farnesyltransferase inhibitors: Mechanism and applications
8. Current status of clinical trials of farnesyltransferase inhibitors
9. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
10. Evolving therapies: Farnesyltransferase inhibitors
11. Absence of the CAAX endoprotease Rce1: Effects on cell growth and transformation
12. Discovery of a novel Raf kinase inhibitor
13. Drugs targeted against protein kinases
14. Raf-1 without MEK?
15. v-Raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells
16. Abrogation of c-Raf expression induces apoptosis in tumor cells
17. Endothelial apoptosis in B-raf deficient mice
18. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
19. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals
20. Rsk1 mediates a MEK-MAP kinase cell survival signal
21. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
22. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase
23. Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria
24. Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation
25. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
26. Phosphorylation and regulation of Raf by Akt (protein kinase B)
27. Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf
28. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
29. Biomarker assays for phosphorylated MAP kinase: Their utility for measurement of MEK inhibition
30. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors